173 related articles for article (PubMed ID: 35938177)
1. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment.
Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A
J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177
[TBL] [Abstract][Full Text] [Related]
2. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
3. Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab.
Starling CT; Messer AA; Kleiman A; McQuade JL; Glitza IC; Torres-Cabala CA; Heberton M
Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670686
[TBL] [Abstract][Full Text] [Related]
4. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study.
Galmiche S; Lheure C; Kramkimel N; Franck N; Boitier F; Dupin N; Turc G; Psimaras D; Aractingi S; Guégan S
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e440-e443. PubMed ID: 31219194
[No Abstract] [Full Text] [Related]
5. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
6. Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature.
Piña Y; Evernden BR; Khushalani N; Margolin K; Tawbi H; Tran ND; Macaulay R; Forsyth P; Peguero E
SAGE Open Med Case Rep; 2021; 9():2050313X211042215. PubMed ID: 34457306
[TBL] [Abstract][Full Text] [Related]
7. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
Wang LX; Quach HT; Moodabigil NV; Davis EJ; Sosman JA; Dusetzina SB; Johnson DB
Cancer; 2020 Jan; 126(2):322-328. PubMed ID: 31580492
[TBL] [Abstract][Full Text] [Related]
8. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma.
Cao Y; Afzal MZ; Shirai K
BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34417242
[TBL] [Abstract][Full Text] [Related]
10. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
Williams TJ; Benavides DR; Patrice KA; Dalmau JO; de Ávila AL; Le DT; Lipson EJ; Probasco JC; Mowry EM
JAMA Neurol; 2016 Aug; 73(8):928-33. PubMed ID: 27271951
[TBL] [Abstract][Full Text] [Related]
11. Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report.
Taillefer VT; Pigeon M; Chen M; Larochelle C; Florescu M; Bélanger K; Adam JP
J Oncol Pharm Pract; 2020 Sep; 26(6):1538-1543. PubMed ID: 32063105
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
13. Severe necrotizing myositis associated with long term anti-neoplastic efficacy following nivolumab plus ipilimumab combination therapy.
Tauber M; Cohen R; Laly P; Josselin L; André T; Mekinian A
Clin Rheumatol; 2019 Feb; 38(2):601-602. PubMed ID: 30456528
[TBL] [Abstract][Full Text] [Related]
14. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced seronegative encephalitis.
Cabral G; Ladeira F; Gil N
J Neuroimmunol; 2020 Oct; 347():577350. PubMed ID: 32768895
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
17. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases.
Zieman D; Frankel AE
J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723
[TBL] [Abstract][Full Text] [Related]
20. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
